Читать книгу Vaccines for Older Adults: Current Practices and Future Opportunities - Группа авторов - Страница 49

1Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D: Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol 2018;40:83–94.

2Wong GCL, Narang V, Lu Y, Camous X, Nyunt MSZ, Carre C, Tan C, Xian CH, Chong J, Chua M, How W, Mok E, Tambyah P, Poidinger M, Abel B, Burdin N, Quemeneur L, Bosco N, Ng TP, Larbi A: Hallmarks of improved immunological responses in the vaccination of more physically active elderly females. Exerc Immunol Rev 2019;25:20–33.

3Weinberger B: Adjuvant strategies to improve vaccination of the elderly population. Curr Opin Pharmacol 2018;41:34–41.

4Del Giudice G, Goronzy JJ, Grubeck-Loebenstein B, Lambert PH, Mrkvan T, Stoddard JJ, Doherty TM: Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging. NPJ Aging Mech Dis 2017;4:1.

5Pera A, Campos C, López N, Hassouneh F, Alonso C, Tarazona R, Solana R: Immunosenescence: implications for response to infection and vaccination in older people. Maturitas 2015;82:50–55.

6Camous X, Visan L, Ying CTT, Abel B, Nyunt MSZ, Narang V, Poidinger M, Carre C, Sesay S, Bosco N, Burdin N, Tambyah PA, Pin NT, Larbi A: Healthy elderly Singaporeans show no age-related humoral hyporesponsiveness nor diminished plasmablast generation in response to influenza vaccine. Immun Ageing 2018;15:28.

7Narang V, Lu Y, Tan C, Camous XFN, Nyunt SZ, Carre C, Mok EWH, Wong G, Maurer-Stroh S, Abel B, Burdin N, Poidinger M, Tambyah PA, Bosco N, Visan L, Ng TP, Larbi A: Influenza vaccine-induced antibody responses are not impaired by frailty in the community-dwelling elderly with natural influenza exposure. Front Immunol 2018;9:2465.

8Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, Rombo L, Sonder G, Smetana J, Heineman T, Bastidas A: Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018;14:1370–1377.

9Weinberger B: Vaccines for the elderly: current use and future challenges. Immun Ageing 2018;15:3.

10Furman D, Davis MM: New approaches to understanding the immune response to vaccination and infection. Vaccine 2015;33:5271–5281.

11Poland GA, Ovsyannikova IG, Kennedy RB: Personalized vaccinology: a review. Vaccine 2018;36:5350–5357.

12Kared H, Martelli S, Tan SW, Simoni Y, Chong ML, Yap SH, Newell EW, Pender SLF, Kamarulzaman A, Rajasu­riar R, Larbi A: Adaptive NKG2C+CD57+ natural killer cell and Tim-3 expression during viral infections. Front Immunol 2018;9:686.

13Iwasaki A, Medzhitov R: Regulation of adaptive immunity by the innate immune system. Science 2010;327:291–295.

14Palgen JL, Tchitchek N, Huot N, Elhmouzi-Younes J, Lefebvre C, Rosenbaum P, Dereuddre-Bosquet N, Martinon F, Hocini H, Cosma A, Müller-Trutwin M, Lévy Y, Le Grand R, Beignon AS: NK cell immune responses differ after prime and boost vaccination. J Leukoc Biol 2019;105:1055–1073.

15Nikzad R, Angelo LS, Aviles-Padilla K, Le DT, Singh VK, Bimler L, Vukmanovic-Stejic M, Vendrame E, Ranganath T, Simpson L, Haigwood NL, Blish CA, Akbar AN, Paust S: Human natural killer cells mediate adaptive immunity to viral antigens. Sci Immunol 2019;4:pii:eaat8116.

16Przemska-Kosicka A, Childs CE, Maidens C, Dong H, Todd S, Gosney MA, Tuohy KM, Yaqoob P: Age-related changes in the natural killer cell response to seasonal influenza vaccination are not influenced by a synbiotic: a randomised controlled trial. Front Immunol 2018;9:591.

17Hazeldine J, Lord JM: The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev 2013;12:1069–1078.

18Phan MT, Chun S, Kim SH, Ali AK, Lee SH, Kim S, Kim SH, Cho D: Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity. Hum Immunol 2017;78:103–112.

19Le Garff-Tavernier M, Béziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debré P, Merle-Beral H, Vieillard V: Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 2010;9:527–535.

20Jiao Y, Huntington ND, Belz GT, Seillet C: Type 1 innate lymphoid cell biology: lessons learnt from natural killer cells. Front Immunol 2016;7:426.

21Mandal A, Viswanathan C: Natural killer cells: in health and disease. Hematol Oncol Stem Cell Ther 2015;8:47–55.

22Waggoner SN, Reighard SD, Gyurova IE, Cranert SA, Mahl SE, Karmele EP, McNally JP, Moran MT, Brooks TR, Yaqoob F, Rydyznski CE: Roles of natural killer cells in antiviral immunity. Curr Opin Virol 2016;16:15–23.

23Small CL, McCormick S, Gill N, Kugathasan K, Santosuosso M, Donaldson N, Heinrichs DE, Ashkar A, Xing Z: NK cells play a critical protective role in host defense against acute extracellular Staphylococcus aureus bacterial infection in the lung. J Immunol 2008;180:5558–5568.

24Sagiv A, Burton DG, Moshayev Z, Vadai E, Wensveen F, Ben-Dor S, Golani O, Polic B, Krizhanovsky V: NKG2D ligands mediate immunosurveillance of senescent cells. Aging (Albany NY) 2016;8:328–344.

25Pereira BI, Devine OP, Vukmanovic-Stejic M, Chambers ES, Subramanian P, Patel N, Virasami A, Sebire NJ, Kinsler V, Valdovinos A, LeSaux CJ, Passos JF, Antoniou A, Rustin MHA, Campisi J, Akbar AN: Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition. Nat Commun 2019;10:2387.

26Waggoner SN, Cornberg M, Selin LK, Welsh RM: Natural killer cells act as rheostats modulating antiviral T cells. Nature 2011;481:394–398.

27Martín-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F: Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004;5:1260–1265.

28Vitale M, Cantoni C, Della Chiesa M, Ferlazzo G, Carlomagno S, Pende D, Falco M, Pessino A, Muccio L, De Maria A, Marcenaro E, Moretta L, Sivori S: An historical overview: the discovery of how NK cells can kill enemies, recruit defense troops, and more. Front Immunol 2019;10:1415.

29Paust S, Blish CA, Reeves RK: Redefining memory: building the case for adaptive NK cells. J Virol 2017;91:pii:e00169-17.

30Sun JC, Ugolini S, Vivier E: Immunological memory within the innate immune system. EMBO J 2014;33:1295–1303.

31Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633–640.

32Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, Moretta L: Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A 2013;83:702–713.

33Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA: The broad spectrum of human natural killer cell diversity. Immunity 2017;47:820–833.

34Freud AG, Yu J, Caligiuri MA: Human natural killer cell development in secondary lymphoid tissues. Semin Immunol 2014;26:132–137.

35Knox JJ, Cosma GL, Betts MR, McLane LM: Characterization of T-bet and eomes in peripheral human immune cells. Front Immunol 2014;5:217.

36Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S: Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013;31:227–258.

37Le Page A, Bourgade K, Lamoureux J, Frost E, Pawelec G, Larbi A, Witkowski JM, Dupuis G, Fülöp T: NK Cells are activated in amnestic mild cognitive impairment but not in mild Alzheimer’s disease patients. J Alzheimers Dis 2015;46:93–107.

38Goodier MR, Jonjić S, Riley EM, Juranić Lisnić V: CMV and natural killer cells: shaping the response to vaccination. Eur J Immunol 2018;48:50–65.

39Collins A, Rothman N, Liu K, Reiner SL: Eomesodermin and T-bet mark developmentally distinct human natural killer cells. JCI Insight 2017;2:e90063.

40Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, Pallett LJ, Peppa D, Dunn C, Fusai G, Male V, Davidson BR, Kennedy P, Maini MK: CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver. Sci Rep 2016;6:26157.

41Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A, Bicciato S, Invernizzi P, Lugli E, Torzilli G, Gershwin ME, Mavilio D: Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun 2016;66:40–50.

42van Helden MJ, de Graaf N, Boog CJ, Topham DJ, Zaiss DM, Sijts AJ: The bone marrow functions as the central site of proliferation for long-lived NK cells. J Immunol 2012;189:2333–2337.

43Blackman MA, Woodland DL: The narrowing of the CD8 T cell repertoire in old age. Curr Opin Immunol 2011;23:537–542.

44López-Botet M, Muntasell A, Martínez-Rodríguez JE, López-Montañés M, Costa-García M, Pupuleku A: Development of the adaptive NK cell response to human cytomegalovirus in the context of aging. Mech Ageing Dev 2016;158:23–26.

45Ljunggren HG, Kärre K: Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance? J Immunogenet 1986;13:141–151.

46Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197–223.

47André P, Castriconi R, Espéli M, Anfossi N, Juarez T, Hue S, Conway H, Romagné F, Dondero A, Nanni M, Caillat-Zucman S, Raulet DH, Bottino C, Vivier E, Moretta A, Paul P: Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol 2004;34:961–971.

48Krzewski K, Coligan JE: Human NK cell lytic granules and regulation of their exocytosis. Front Immunol 2012;3:335.

49Chavez-Galan L, Arenas-Del Angel MC, Zenteno E, Chavez R, Lascurain R: Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 2009;6:15–25.

50Majewska-Szczepanik M, Paust S, von Andrian UH, Askenase PW, Szczepanik M: Natural killer cell-mediated contact sensitivity develops rapidly and depends on interferon-α, interferon-γ and interleukin-12. Immunology 2013;140:98–110.

51Farsakoglu Y, Palomino-Segura M, Latino I, Zanaga S, Chatziandreou N, Pizzagalli DU, Rinaldi A, Bolis M, Sallusto F, Stein JV, Gonzalez SF: Influenza vaccination induces NK-cell-mediated type-II IFN response that regulates humoral immunity in an IL-6-dependent manner. Cell Rep 2019;26:2307–2315.e5.

52Urlaub D, Höfer K, Müller ML, Watzl C: LFA-1 Activation in NK cells and their subsets: influence of receptors, maturation, and cytokine stimulation. J Immunol 2017;198:1944–1951.

53Burt BM, Plitas G, Stableford JA, Nguyen HM, Bamboat ZM, Pillarisetty VG, DeMatteo RP: CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis. J Leukoc Biol 2008;84:1039–1046.

54Palgen JL, Tchitchek N, Elhmouzi-Younes J, Delandre S, Namet I, Rosenbaum P, Dereuddre-Bosquet N, Martinon F, Cosma A, Lévy Y, Le Grand R, Beignon AS: Prime and boost vaccination elicit a distinct innate myeloid cell immune response. Sci Rep 2018;8:3087.

55Pampena MB, Levy EM: Natural killer cells as helper cells in dendritic cell cancer vaccines. Front Immunol 2015;6:13.

56Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G: Reciprocal activating interaction between naturalkiller cells and dendritic cells. J Exp Med 2002;195:327–333.

57Amakata Y, Fujiyama Y, Andoh A, Hodohara K, Bamba T: Mechanism of NK cellactivation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin Exp Immunol 2001;124:214–222.

58Della Chiesa M, Romagnani C, Thiel A, Moretta L, Moretta A: Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte derived dendritic cells during innate immune responses. Blood 2006;108:3851–3858.

59Ferlazzo G, Pack M, Thomas D, Paludan C, Schmid D, Strowig T: Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 2004;101:16606–16611.

60Moretta A, Marcenaro E, Sivori S, DellaChiesa M, Vitale M, Moretta L: Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol 2005;26:668–675.

61Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405–411.

62Piccioli D, Sbrana S, Melandri E, Valiante NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002;195:335–341.

63Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C: Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343–351.

64Rydyznski CE, Cranert SA, Zhou JQ, Xu H, Kleinstein SH, Singh H, Waggoner SN: Affinity maturation is impaired by natural killer cell suppression of germinal centers. Cell Rep 2018;24:3367–3373.e4.

65Gounder SS, Abdullah BJJ, Radzuanb NEIBM, Zain FDBM, Sait NBM, Chua C, Subramani B: Effect of aging on NK cell population and their proliferation at ex vivo culture condition. Anal Cell Pathol (Amst) 2018;2018:7871814.

66Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A: Human NK cell response to pathogens. Semin Immunol 2014;26:152–160.

67Raulet DH, Guerra N: Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009;9:568–580.

68Rodier F, Campisi J: Four faces of cellular senescence. J Cell Biol 2011;192:547–556.

69Camous X, Pera A, Solana R, Larbi A: 2012. NK cells in healthy aging and age-associated diseases. J Biomed Biotechnol 2012;2012:195956.

70Solana R, Campos C, Pera A, Tarazona R: Shaping of NK cell subsets by aging. Curr Opin Immunol 2014;29:56–61.

71Campos C, Pera A, Sanchez-Correa B, Alonso C, Lopez-Fernandez I, Morgado S, Tarazona R, Solana R: Effect of age and CMV on NK cell subpopulations. Exp Gerontol 2014;54:130–137.

72Al-Attar A, Presnell SR, Peterson CA, Thomas DT, Lutz CT: The effect of sex on immune cells in healthy aging: Elderly women have more robust natural killer lymphocytes than do elderly men. Mech Ageing Dev 2016;156:25–33.

73Reed RG, Al-Attar A, Presnell SR, Lutz CT, Segerstrom SC: A longitudinal study of the stability, variability, and interdependencies among late-differentiated T and NK cell subsets in older adults. Exp Gerontol 2019;121:46–54.

74Reed RG, Presnell SR, Al-Attar A, Lutz CT, Segerstrom SC: Perceived stress, cytomegalovirus titers, and late-differentiated T and NK cells: between-, within-person associations in a longitudinal study of older adults. Brain Behav Immun 2019;80:266–274.

75Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T: Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 2012;24:331–341.

76Campos C, Pera A, Lopez-Fernandez I, Alonso C, Tarazona R, Solana R: Proinflammatory status influences NK cells subsets in the elderly. Immunol Lett 2014;162:298–302.

77Mariani E, Meneghetti A, Neri S, Ravaglia G, Forti P, Cattini L, Facchini A: Chemokine production by natural killer cells from nonagenarians. Eur J Immunol 2002;32:1524–1529.

78Wang J, Geiger H, Rudolph KL: Immunoaging induced by hematopoietic stem cell aging. Curr Opin Immunol 2011;23:532–536.

79Solana R, Mariani E: NK and NK/T cells in human senescence. Vaccine 2000;18:1613–1620.

80Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, Bengochea ML, Duran E, Solana R, Tarazona R: Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 2011;60:1195–1205.

81Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R: Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 2012;90:109–115.

82Tarazona R, Campos C, Pera A, Sanchez-Correa B, Solana R: Flow cytometry analysis of NK cell phenotype and function in aging. Methods Mol Biol 2015;1343:9–18.

83Mariani E, Mariani AR, Meneghetti A, Tarozzi A, Cocco L, Facchini A: Age-dependent decreases of NK cell phosphoinositide turnover during spontaneous but not Fc-mediated cytolytic activity. Int Immunol 1998;10:981–989.

84Campos C, López N, Pera A, Gordillo JJ, Hassouneh F, Tarazona R, Solana R: Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age. Biogerontology 2015;16:671–683.

85Bigley AB, Spielmann G, Agha N, O’Connor DP, Simpson RJ: Dichotomous effects of latent CMV infection on the phenotype and functional properties of CD8+ T-cells and NK-cells. Cell Immunol 2016;300:26–32.

86López-Botet M, Muntasell A, Vilches C: The CD94/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection. Semin Immunol 2014;26:145–151.

87Gumá M, Angulo A, Vilches C, Gómez-Lozano N, Malats N, López-Botet M: Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004;104:3664–3671.

88Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, Achdout H, Ghadially H, Dor Y, Nir T, Doviner V, Hershkovitz O, Mendelson M, Naparstek Y, Mandelboim O: The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 2010;11:121–128.

89 Ogata K, An E, Shioi Y, Nakamura K, Luo S, Yokose N, Minami S, Dan K: Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol 2001;124:392–397.

90Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000;356:1795–1799.

91Hak Ł, Myśliwska J, Więckiewicz J, Szyndler K, Trzonkowski P, Siebert J, Myśliwski A: NK cell compartment in patients with coronary heart disease. Immun Ageing 2007;4:3.

92Cerwenka A, Lanier LL: Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol 2016;16:112–123.

93Castle SC: Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000;31:578–585.

94van Deursen JM: The role of senescent cells in ageing. Nature 2014;509:439–446.

95Campisi J, Robert L: Cell senescence: role in aging and age-related diseases. Interdiscip Top Gerontol 2014;39:45–61.

96Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, Kirkland JL, van Deursen JM: Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011;479:232–236.

97Sagiv A, Biran A, Yon M, Simon J, Lowe SW, Krizhanovsky V: Granule exocytosis mediates immune surveillance of senescent cells. Oncogene 2013; 32: 1971–1977.

98Hazeldine J, Hampson P, Lord JM: Reduced release and binding of perforin at the immunological synapse underlies the age-related decline in natural killer cell cytotoxicity. Aging Cell 2012; 11: 751–759.

99Mariani E, Mariani AR, Meneghetti A, Tarozzi A, Cocco L, Facchini A: Age-dependent decreases of NK cell phosphoinositide turnover during spontaneous but not Fc-mediated cytolytic activity. Int Immunol 1998; 10: 981–989.

100Myśliwska J, Myśliwski A, Witkowski J: Age-dependent decline of natural killer and antibody-dependent cell mediated cytotoxicity activity of human lymphocytes is connected with decrease of their acid phosphatase activity. Mech Ageing Dev 1985;31:1–11.

101Myśliwska J, Bigda J, Myśliwski A: Activity of acid phosphatase in target binding cells expressing NK cytotoxic potential. Acta Histochem 1987;82:127–131.

102McVicar DW, Burshtyn DN: Intracellular signaling by the killer immunoglobulin-like receptors and Ly49. Sci STKE 2001;2001:re1.

103Fülöp T, Larbi A, Witkowski JM: Human Inflammaging. Gerontology 2019;65:495–504.

104Fulop T, Witkowski JM, Olivieri F, Larbi A: The integration of inflammaging in age-related diseases. Semin Immunol 2018;40:17–35.

105Fülöp T, Larbi A, Pawelec G: Human T cell aging and the impact of persistent viral infections. Front Immunol 2013;4:271.

106Sansoni P, Vescovini R, Fagnoni FF, Akbar A, Arens R, Chiu YL, et al: New advances in CMV and immunosenescence. Exp Gerontol 2014;55:54–62.

107Monsiváis-Urenda A, Noyola-Cherpitel D, Hernández-Salinas A, García-Sepúlveda C, Romo N, Baranda L, López-Botet M, González-Amaro R: Influence of human cytomegalovirus infection on the NK cell receptor repertoire in children. Eur J Immunol 2010;40:1418–1427.

108Zhang T, Scott JM, Hwang I, Kim S: Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency. J Immunol 2013;190:1402–1406.

109Béziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Björklund AT, Retière C, Sverremark-Ekström E, Traherne J, Ljungman P, Schaffer M, Price DA, Trowsdale J, Michaëlsson J, Ljunggren HG, Malmberg KJ: NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 2013;121:2678–2688.

110Luetke-Eversloh M, Hammer Q, Durek P, Nordström K, Gasparoni G, Pink M, Hamann A, Walter J, Chang HD, Dong J, Romagnani C: Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog 2014;10:e1004441.

111Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, Han H, Chiang SC, Foley B, Mattsson K, Larsson S, Schaffer M, Malmberg KJ, Ljunggren HG, Miller JS, Bryceson YT: Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015;42:443–456.

112Müller-Durovic B, Grählert J, Devine OP, Akbar AN, Hess C: CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age. Aging (Albany, NY) 2019;11:724–740.

113Wu Z, Sinzger C, Frascaroli G, Reichel J, Bayer C, Wang L, Schirmbeck R, Mertens T: Human cytomegalovirus-induced NKG2C(hi) CD57(hi) natural killer cells are effectors dependent on humoral antiviral immunity. J Virol 2013;87:7717–7725.

114Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, Scott JM, Kamimura Y, Lanier LL, Kim S: Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 2015;42:431–442.

115Liu LL, Landskron J, Ask EH, Enqvist M, Sohlberg E, Traherne JA, Hammer Q, Goodridge JP, Larsson S, Jayaraman J, Oei VYS, Schaffer M, Taskén K, Ljunggren HG, Romagnani C, Trowsdale J, Malmberg KJ, Béziat V: Critical role of CD2 co-stimulation in adaptive natural killer cell responses revealed in NKG2C-deficient humans. Cell Rep 2016;15:1088–1099.

116Rölle A, Halenius A, Ewen EM, Cerwenka A, Hengel H, Momburg F: CD2-CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection. Eur J Immunol 2016;46:2420–2425.

117Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, Han H, Chiang SC, Foley B, Mattsson K, Larsson S, Schaffer M, Malmberg KJ, Ljunggren HG, Miller JS, Bryceson YT: Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015;42:443–456.

118Makwana NB, Foley B, Lee S, Fernandez S, Irish AB, Price P: Asymptomatic CMV infections in long-term renal transplant recipients are associated with the loss of FcRγ from LIR-1+ NK cells. Eur J Immunol 2016;46:2597–2608.

119Della Chiesa M, Falco M, Bertaina A, Muccio L, Alicata C, Frassoni F, Locatelli F, Moretta L, Moretta A: Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C–/– umbilical cord blood. J Immunol 2014;192:1471–1479.

120120. iranda D, Jara C, Mejias S, Ahumada V, Cortez-San Martin M, Ibañez J, Hirsch S, Montoya M: Deficient mitochondrial biogenesis in IL-2 activated NK cells correlates with impaired PGC1-α upregulation in elderly humans. Exp Gerontol 2018;110:73–78.

121He XS, Draghi M, Mahmood K, Holmes TH, Kemble GW, Dekker CL, Arvin AM, Parham P, Greenberg HB: T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest 2004;114:1812–1819.

122Jost S, Tomezsko PJ, Rands K, Toth I, Lichterfeld M, Gandhi RT, Altfeld M: CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination. J Virol 2014;88:8349–8354.

123Krishnaraj R, Bhooma T: Cytokine sensitivity of human NK cells during immunosenescence. 2. IL2-induced interferon gamma secretion. Immunol Lett 1996;50:59–63.

124Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, Peña J, Solana R: NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 1999;34:253–265.

125Larbi A, Dupuis G, Khalil A, Douziech N, Fortin C, Fülöp T Jr: Differential role of lipid rafts in the functions of CD4+ and CD8+ human T lymphocytes with aging. Cell Signal 2006;18:1017–1030.

126Myśliwska J, Bryl E, Trzonkowski P, Myśliwski A: Compensatory effect of TNFalpha on low natural killer activity in the elderly. Acta Biochim Pol 2000;47:301–311.

127Santos MS, Meydani SN, Leka L, Wu D, Fotouhi N, Meydani M, Hennekens CH, Gaziano JM: Natural killer cell activity in elderly men is enhanced by beta-carotene supplementation. Am J Clin Nutr 1996;64:772–777.

128Pearce EL, Pearce EJ: Metabolic pathways in immune cell activation and quiescence. Immunity 2013;38:633–643.

129Rostamzadeh D, Yousefi M, Haghshenas MR, Ahmadi M, Dolati S, Babaloo Z: mTOR Signaling pathway as a master regulator of memory CD8+ T-cells, Th17, and NK cells development and their functional properties. J Cell Physiol 2019;234:12353–12368.

130Marçais A, Marotel M, Degouve S, Koenig A, Fauteux-Daniel S, Drouillard A, Schlums H, Viel S, Besson L, Allatif O, Bléry M, Vivier E, Bryceson Y, Thaunat O, Walzer T: High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors. Elife 2017;6:pii:e26423.

131Donnelly RP, Loftus RM, Keating SE, Liou KT, Biron CA, Gardiner CM, Finlay DK: mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J Immunol 2014;193:4477–4484.

132Keppel MP, Saucier N, Mah AY, Vogel TP, Cooper MA: Activation-specific metabolic requirements for NK Cell IFN-γ production. J Immunol 2015;194:1954–1962.

133Keating SE, Zaiatz-Bittencourt V, Loftus RM, Keane C, Brennan K, Finlay DK, Gardiner CM: Metabolic reprogramming supports IFN-γ production by CD56bright NK cells. J Immunol 2016;196:2552–2560.

134Miranda D, Jara C, Ibañez J, Ahumada V, Acuña-Castillo C, Martin A, Córdova A, Montoya M: PGC-1α-dependent mitochondrial adaptation is necessary to sustain IL-2-induced activities in human NK cells. Mediators Inflamm 2016;2016:9605253.

135Min-Oo G, Kamimura Y, Hendricks DW, Nabekura T, Lanier LL: Natural killer cells: walking three paths down memory lane. Trends Immunol 2013;34:251–258.

136Nabekura T, Lanier LL: Tracking the fate of antigen-specific versus cytokine-activated natural killer cells after cytomegalovirus infection. J Exp Med 2016;213:2745–2758.

137Nielsen CM, White MJ, Bottomley C, Lusa C, Rodríguez-Galán A, Turner SE, Goodier MR, Riley EM: Impaired NK cell responses to pertussis and H1N1 influenza vaccine antigens in human cytomegalovirus-infected individuals. J Immunol 2015;194:4657–4667.

138Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM: Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA 2009;106:1915–1919.

139Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA: Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant 2014;20:463–473.

140Bastola R, Noh G, Keum T, Bashyal S, Seo JE, Choi J, Oh Y, Cho Y, Lee S: Vaccine adjuvants: smart components to boost the immune system. Arch Pharm Res 2017;40:1238–1248.

141Manser AR, Uhrberg M: Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance. Cancer Immunol Immunother 2016;65:417–426.

142Bengnér M, Béziat V, Ernerudh J, Nilsson BO, Löfgren S, Wikby A, Malmberg KJ, Strindhall J: Independent skewing of the T cell and NK cell compartments associated with cytomegalovirus infection suggests division of labor between innate and adaptive immunity. Age (Dordr) 2014;36:571–582.

143Andrew MK, Bowles SK, Pawelec G, Haynes L, Kuchel GA, McNeil SA, McElhaney JE: Influenza vaccination in older adults: recent innovations and practical applications. Drugs Aging 2019;36:29–37.

144Lal H, Cunningham AL, Heineman TC: Adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;373:1576–1577.

145Doherty TM, Del Giudice G, Maggi S: Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion. Ann Med 2019;51:128–140.

146McElhaney JE, Andrew MK, McNeil SA: Estimating influenza vaccine effectiveness: Evolution of methods to better understand effects of confounding in older adults. Vaccine 2017;35:6269–6274.

147Merani S, Kuchel GA, Kleppinger A, McElhaney JE: Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol 2018;107:116–125.

148Nichols MK, Andrew MK, Hatchette TF, Ambrose A, Boivin G, Bowie W, et al; Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN), the Toronto Invasive Bacterial Diseases Network (TIBDN): Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: a pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine 2018;36:2166–2175.

149Moro-García MA, Alonso-Arias R, López-Vázquez A, Suárez-García FM, Solano-Jaurrieta JJ, Baltar J, López-Larrea C: Relationship between functional ability in older people, immune system status, and intensity of response to CMV. Age (Dordr) 2012;34:479–495.

150Furman D, Jojic V, Sharma S, Shen-Orr SS, Angel CJ, Onengut-Gumuscu S, Kidd BA, Maecker HT, Concannon P, Dekker CL, Thomas PG, Davis MM: Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med 2015;7:281ra43.

151Kastenmüller W, Torabi-Parizi P, Subramanian N, Lämmermann T, Germain RN: A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell 2012;150:1235–1248.

152Wilder JA, Koh CY, Yuan D: The role of NK cells during in vivo antigen-specific antibody responses. J Immunol 1996;156:146–152.

153Hunter CA, Jones SA: IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448–457.

154Bigley AB, Rezvani K, Shah N, Sekine T, Balneger N, Pistillo M, Agha N, Kunz H, O’Connor DP, Bollard CM, Simpson RJ: Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans. Clin Exp Immunol 2016;185:239–251.

155Bigley AB, Rezvani K, Shah N, Sekine T, Balneger N, Pistillo M, Agha N, Kunz H, O’Connor DP, Bollard CM, Simpson RJ: Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans. Clin Exp Immunol 2016;185:239–251.

156Kirkland JL, Tchkonia T, Zhu Y, Niedernhofer LJ, Robbins PD: The clinical potential of senolytic drugs. J Am Geriatr Soc 2017;65:2297–2301.

Tamàs Fülöp, MD, PhD

Research Center on Aging, Faculty of Medicine and Health Sciences

University of Sherbrooke, 3001, 12th Avenue North

Sherbrooke, QC J1H 5N4 (Canada)

E-Mail Tamas.Fulop@Usherbrooke.ca